MicroPort Endovascular MedTech Ltd (688016) — Capital Reinvestment Ratio

Latest as of September 2025: 1.84x

MicroPort Endovascular MedTech Ltd (688016) has a Capital Reinvestment Ratio of 1.84x as of September 2025, meaning it reinvests 2% of its operating cash flow (CN¥46.79 Million) in capital expenditures (CN¥86.03 Million). Check 688016 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.84x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥46.79 Million
CNY

Capital Expenditures

CN¥86.03 Million
CNY

Data as of

Sep 2025
Most recent filing

MicroPort Endovascular MedTech Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks MicroPort Endovascular MedTech Ltd's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see 688016 cash flow metrics.

Annual Capital Reinvestment Ratio for MicroPort Endovascular MedTech Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for MicroPort Endovascular MedTech Ltd from 2016 to 2025. See 688016 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.53x CN¥573.06 Million CN¥303.03 Million ▼ -7.1%
2024 0.57x CN¥373.60 Million CN¥212.65 Million ▲ +70.9%
2023 0.33x CN¥571.22 Million CN¥190.26 Million ▼ -62.2%
2022 0.88x CN¥333.76 Million CN¥293.98 Million ▲ +195.2%
2021 0.30x CN¥300.25 Million CN¥89.58 Million ▲ +147.4%
2020 0.12x CN¥217.44 Million CN¥26.22 Million ▼ -18.7%
2019 0.15x CN¥143.20 Million CN¥21.24 Million ▼ -36.4%
2018 0.23x CN¥106.85 Million CN¥24.90 Million ▼ -42.7%
2017 0.41x CN¥69.36 Million CN¥28.23 Million ▼ -61.4%
2016 1.06x CN¥30.13 Million CN¥31.81 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow